Myriad Genetics to Present at 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Myriad Genetics (NASDAQ: MYGN) announced that Sam Raha, president and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, Jan. 14, 2026 at 5:15 pm PT (8:15 pm ET). The presentation will be available via a live webcast and an archived replay at the company’s investor website: investor.myriad.com.
Positive
- None.
Negative
- None.
News Market Reaction – MYGN
In the Jan 6 session, MYGN gained 6.19%, reflecting a notable positive market reaction. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Dec 09 | Conference research data | Positive | +4.0% | Presentation of 8 SABCS abstracts including MRD and expanded MyRisk data. |
| Nov 25 | Product collaboration | Positive | -3.9% | Launch of integrated AI and genetic breast health risk platform with partners. |
| Nov 11 | Investor conferences | Neutral | +3.1% | Planned participation in Wolfe and Piper Sandler healthcare investor conferences. |
| Nov 10 | Product expansion | Positive | +2.9% | Added 15 genes to MyRisk, expanding to 63 guideline-aligned hereditary cancer genes. |
| Nov 06 | Conference research data | Positive | -3.8% | Planned 11 new studies at NSGC conference on oncology and reproductive testing. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent company news often centers on conferences and product/clinical updates, with a mix of aligned and divergent price reactions, indicating that seemingly positive announcements have not consistently driven upside.
Over the last few months, Myriad Genetics has emphasized scientific visibility and product expansion. It highlighted 11 genetic testing studies at the NSGC 2025 conference and later expanded its MyRisk panel to 63 genes across more than 11 cancer types. The company then announced participation in late-2025 investor conferences and, in December, slated 8 abstracts for SABCS, showcasing its MRD and hereditary cancer capabilities. Today’s J.P. Morgan appearance continues this pattern of using major forums to communicate strategy and data.
Key Terms
molecular diagnostic testing medical
precision medicine medical
webcast technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
SALT LAKE CITY, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that Sam Raha, president and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, Jan. 14, at 5:15 pm PT (8:15 pm ET).
The presentation will be available through a live webcast and archived at investor.myriad.com.
About Myriad Genetics
Myriad Genetics is a leading molecular diagnostic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad Genetics develops and offers molecular tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care and lower healthcare costs. For more information, visit www.myriad.com.
Investor Contact
Matt Scalo
(801) 584-3532
IR@myriad.com
Media Contact
Kate Schraml
(224) 875-4493
PR@myriad.com
